RT Journal Article
SR Electronic
T1 Once-daily QVA149 provides superior improvements in lung function compared with glycopyrronium and tiotropium in severe COPD patients: A 52 week pooled analysis
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P755
VO 42
IS Suppl 57
A1 Donald Banerji
A1 Angel FowlerTaylor
A1 Pearl Kho
A1 Hungta Chen
A1 Vijay Alagappan
YR 2013
UL http://erj.ersjournals.com/content/42/Suppl_57/P755.abstract
AB IntroductionQVA149 is a once daily, dual bronchodilator with a fixed-dose combination of indacaterol (a long-acting β2-agonist) and glycopyrronium (a long-acting muscarinic antagonist) for treatment of patients with COPD. We present the pooled analysis of lung function data from severe patients from the QVA149 SPARK, ARISE, and ENLIGHTEN studies.MethodsData from 1871 patients with severe COPD (stage III; post-bronchodilator forced expiratory volume in 1 s (FEV1) ≥30-<50% of predicted and FEV1/FVC <70%) were pooled (QVA149 [110/50µg] = 696; glycopyrronium [50µg] = 584; tiotropium [18µg] = 591). FEV1 and forced vital capacity (FVC) were analyzed using ANCOVA.ResultsDemographics and baseline characteristics were balanced across the treatment groups; overall 63.8 yrs mean age, 80.1% Caucasians, 6.9 yrs mean duration of COPD, 72.4% patients used inhaled corticosteroids at baseline, 37.9% current smoker, and 41.4% of FEV1/FVC. Pre-dose FEV1 and FVC were significantly greater with QVA149 than glycopyrronium and tiotropium at all visits (p<0.001). Spirometric analyses of QVA149 vs. glycopyrronium and tiotropium after 52 weeks of treatment are shown in table.View this table:Table: Treatment differences in lung functionConclusionQVA149 improved lung function significantly better than glycopyrronium and tiotropium in patients with severe COPD at Week 52.